Alignment Healthcare (ALHC) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $22.00 from $26.00 | Aug 4, 2026 |
| Raymond James | Downgraded | Strong Buy → Outperform | $19.00 from $22.00 | Aug 3, 2026 |
| Barclays | Maintained | Equal-Weight | $16.00 from $19.00 | May 26, 2026 |
| Barclays | Maintained | Equal-Weight | $19.00 from $18.00 | May 1, 2026 |
| UBS | Maintained | Neutral | $22.00 from $21.00 | May 1, 2026 |
| JP Morgan | Maintained | Overweight | $26.00 from $23.00 | Feb 5, 2026 |
| TD Cowen | Maintained | Buy | $25.00 from $18.50 | Jan 16, 2026 |
| UBS | Maintained | Neutral | $21.00 from $18.00 | Jan 14, 2026 |
| Piper Sandler | Maintained | Overweight | $30.00 from $20.00 | Jan 6, 2026 |
| JP Morgan | Maintained | Overweight | $23.00 from $20.00 | Dec 17, 2025 |
| JP Morgan | Upgraded | Neutral → Overweight | $20.00 from $18.00 | Nov 24, 2025 |
| JP Morgan | Maintained | Neutral | $18.00 from $17.00 | Nov 5, 2025 |
| Barclays | Maintained | Equal-Weight | $18.00 from $13.00 | Nov 3, 2025 |
| UBS | Maintained | Neutral | $18.00 from $17.00 | Oct 31, 2025 |
| Goldman Sachs | Initiated Coverage | Buy | $21.00 | Oct 14, 2025 |
| Keybanc | Upgraded | Sector Weight → Overweight | $21.00 | Aug 25, 2025 |
| Barclays | Upgraded | Underweight → Equal-Weight | $13.00 from $9.00 | Jul 31, 2025 |
| UBS | Maintained | Neutral | $17.00 from $16.00 | May 2, 2025 |
| Baird | Maintained | Outperform | $22.00 from $17.00 | Apr 15, 2025 |
| Stifel | Maintained | Buy | $23.00 from $18.00 | Apr 8, 2025 |
Frequently asked questions
Is ALHC a buy, sell, or hold?
Analysts covering Alignment Healthcare currently average a Buy rating: 12 buy, 2 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ALHC?
On Aug 4, 2026, JP Morgan maintained Alignment Healthcare at Overweight with a price target of $22.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.